PMID- 27118338
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20181113
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Print)
IS  - 0163-7258 (Linking)
VI  - 164
DP  - 2016 Aug
TI  - State-of-the-art of regulatory dendritic cells in cancer.
PG  - 97-104
LID - S0163-7258(16)30043-2 [pii]
LID - 10.1016/j.pharmthera.2016.04.003 [doi]
AB  - Dendritic cells (DCs) with robust immunosuppressive activity are commonly found 
      in the microenvironment of advanced solid tumors. These innate immune cells are 
      generically termed regulatory DCs and include various subsets such as 
      plasmacytoid, conventional and monocyte-derived/inflammatory populations whose 
      normal function is subverted by tumor-derived signals. This review summarizes 
      recent findings on the nature and function of regulatory DCs, their relationship 
      with other myeloid subsets and unique therapeutic opportunities to abrogate 
      malignant progression through their targeting.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Conejo-Garcia, Jose R
AU  - Conejo-Garcia JR
AD  - Tumor Microenvironment and Metastasis Program, The Wistar Institute, 
      Philadelphia, PA 19104, USA. Electronic address: jrconejo@Wistar.org.
FAU - Rutkowski, Melanie R
AU  - Rutkowski MR
AD  - Department of Microbiology, Immunology, and Cancer Biology, Carter Immunology 
      Center, University of Virginia, Charlottesville, VA 22908, USA.
FAU - Cubillos-Ruiz, Juan R
AU  - Cubillos-Ruiz JR
AD  - Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, 
      NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical 
      College, New York, NY 10065, USA.
LA  - eng
GR  - P30 CA010815/CA/NCI NIH HHS/United States
GR  - R01 CA124515/CA/NCI NIH HHS/United States
GR  - R01 CA157664/CA/NCI NIH HHS/United States
GR  - R01 CA178687/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160423
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Matrix Attachment Region Binding Proteins)
RN  - 0 (SATB1 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/immunology/*metabolism
MH  - Dinoprostone/metabolism
MH  - Humans
MH  - Immune Tolerance/immunology
MH  - Macrophages/metabolism
MH  - Matrix Attachment Region Binding Proteins/biosynthesis
MH  - Myelopoiesis/immunology
MH  - Nanostructures
MH  - Neoplasms/immunology/*physiopathology
MH  - Transforming Growth Factor beta/metabolism
PMC - PMC4942379
MID - NIHMS783978
OTO - NOTNLM
OT  - Dendritic cell
OT  - Emergency myelopoiesis
OT  - Immunosuppression
OT  - Tumor immunology
OT  - Tumor microenvironment
COIS- CONFLICT OF INTEREST STATEMENT All the authors declare no conflict of interest.
EDAT- 2016/04/28 06:00
MHDA- 2017/08/02 06:00
PMCR- 2017/08/01
CRDT- 2016/04/28 06:00
PHST- 2016/02/29 00:00 [received]
PHST- 2016/04/05 00:00 [accepted]
PHST- 2016/04/28 06:00 [entrez]
PHST- 2016/04/28 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - S0163-7258(16)30043-2 [pii]
AID - 10.1016/j.pharmthera.2016.04.003 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2016 Aug;164:97-104. doi: 10.1016/j.pharmthera.2016.04.003. Epub 
      2016 Apr 23.